已收盤 10-17 16:00:00 美东时间
-0.220
-1.58%
Kyivstar (KYIV) and Mastercard have signed a memorandum of cooperation to develop technological solutions for the country’s financial infrastructure and promote cashless payments. The partnership will...
10-15 21:13
Kyivstar (NASDAQ:KYIV), Ukraine's leading digital operator, and global technology company Mastercard have signed a Memorandum of Cooperation, marking the beginning of a strategic partnership between the companies. Their
10-15 21:08
Kyivstar and Mastercard have signed a Memorandum of Cooperation to develop innovative technologies for Ukraine's financial infrastructure, promote cashless payments, and expand access to financial services. They plan to test Starlink Direct to Cell satellite technology for financial transactions in areas with no mobile coverage, as well as collaborate on new financial products and services leveraging Big Data and analytics. The partnership aims t...
10-15 13:00
Kyivstar, Ukraine's leading digital operator, has launched a major network modernization project from 2025 to 2026 to improve service quality, expand 4G capacity, and prepare for 5G rollout. The initiative includes upgrading outdated equipment, enhancing data speeds, and boosting network stability, especially in high-traffic areas. Preliminary results show a 30% increase in data transfer speeds and a 50% rise in network capacity at upgraded sites...
10-06 08:00
Kyivstar Group Ltd has integrated AI technologies into its Kyivstar Cloud platform, enabling Ukrainian businesses and government institutions to deploy AI solutions domestically. This move, according to Kostiantyn Vechir, marks a significant step in enhancing Ukraine's digital resilience, offering capabilities like real-time big data analytics, process automation, custom AI models, and ready-to-use tools without needing an in-house AI team. Kyivs...
09-29 09:21
今日重点评级关注:Ascendiant Capital:维持Aytu BioPharma"买入"评级,目标价从12美元升至12.5美元;Oppenheimer:维持Immuneering"跑赢大市"评级,目标价从21美元升至30美元
09-26 09:45
今日重点评级关注:Ascendiant Capital:维持Maison Solutions"买入"评级,目标价从4美元升至4.25美元;瑞穗:维持MBX Biosciences"跑赢大市"评级,目标价从38美元升至56美元
09-25 09:52
Oppenheimer analyst Timothy Horan initiates coverage on Kyivstar Group (NASDAQ:KYIV) with a Outperform rating and announces Price Target of $20.
09-24 21:08
今日重点评级关注:Benchmark:维持Unicycive Therapeutics"投机性买入"评级,目标价从3美元升至21美元;Guggenheim:维持Amylyx Pharmaceuticals"买入"评级,目标价从17美元升至25美元
09-16 09:48
Rothschild & Co analyst Steve Malcolm initiates coverage on Kyivstar Group (NASDAQ:KYIV) with a Buy rating and announces Price Target of $15.3.
09-15 21:55